Navigation Links
Stem Cell Assurance Announces Hiring of Vice President of Research and Development
Date:4/13/2011

JUPITER, Fla., April 13, 2011 /PRNewswire/ -- Stem Cell Assurance, Inc. (SCLZ) has announced that Francisco J. Silva has been hired as its Vice President of Research and Development. Mr. Silva is expected to play a key role in leading the company's laboratory biological tool initiative and by developing a product portfolio targeted to meet the demands of large pharmaceutical companies' drug discovery and development platforms.  

Since 2007, Mr. Silva has served as CEO of DV Biologics LLC, and as President of DV Biosciences LLC, companies engaged in the commercialization of human based biologics for both research and therapeutic applications.  Mr. Silva's experience includes a previous position as VP of Research and Development for PrimeGen Biotech LLC, where he was responsible for developing the company's cell based platforms.  He has held teaching positions at Cal State Polytechnic University and was a reviewer for the Cell Transplantation journal.  He is also a published author and presenter on the subject of stem cells, is a member of the International Society of Cell Therapy Cell Commercialization Committee, and holds multiple stem cell patents.

Mark Weinreb, CEO of Stem Cell Assurance, said, "We are very pleased to welcome Mr. Silva to the Stem Cell Assurance team, bringing with him an accomplished scientific career.  His leadership within the biological tool field allows for the Company to utilize his contacts and skills for potential near term revenue while the company develops its long term growth plan."  

Mr. Silva commented, "I'm very excited about joining Stem Cell Assurance and to help the Company begin its path to developing new and innovative cell-based opportunities and technology.  I look forward to establishing a world class laboratory to expand our stem cell development and therapeutic programs, in addition to developing intellectual property."  

About Stem Cell Assurance, Inc.

Stem Cell Assurance, Inc.'s goal is to become a medical center of excellence using cell and tissue regenerative therapy protocols, primarily involving a patient's own (autologous) adult stem cells (non-embryonic), allowing patients to undergo cellular-based treatments. As more and more cellular therapies become standard of care, the Company believes its strength will be its focus on the unity of medical and scientific explanations for its future clinical procedures and outcomes and its incorporation of adult stem cell collection and storage services for future personal medical applications.  The Company also operates a wholly-owned subsidiary, Stem Cellutrition™, which plans to offers facial creams and other skin care products.

CONTACTS

Mark Weinreb

CEO

Tel: (561) 904-6070

Fax: (561) 429-5684


'/>"/>
SOURCE Stem Cell Assurance, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Cytochroma appoints Steven I. Engel as Vice President of Regulatory Affairs and Quality Assurance
2. Hector Garcia Joins Particle Sciences as Director of Quality Assurance
3. Blue Dye Test Alternative Installed at Bayer China for Packaging Quality Assurance Process
4. Sepha's Blue Dye Test Alternative Brings ‘Complete Automation' To Pharma-Packaging Quality Assurance
5. Stem Cell Assurance Unveils Physician Network Offering Regenerative Cell Cosmetic and Reconstructive Applications
6. Joseph J. Ross, M.D., F.A.C.S. Joins Stem Cell Assurance as Vice Chairman
7. Stem Cell Assurance Announces Appointment of Mark Weinreb, M.S. as Chief Executive Officer and Board Member
8. Stem Cell Assurance to Open New Laboratory Facility in Jupiter, Florida
9. Stem Cell Assurance Announces Engagement of Marcum LLP as its Independent Auditors
10. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
11. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... DIEGO, Dec. 8, 2016  OncoSec Medical Incorporated ... developing DNA-based intratumoral cancer immunotherapies, today announced financial ... "We are delivering on our commitment ... with ImmunoPulse® IL-12. We are pleased with the ... combination trial, and we are focused on advancing ...
(Date:12/8/2016)... , Dec. 8, 2016 Eurofins announces the appointment of ... President of Eurofins Scientific Inc. (ESI). Mr. Murray ... proven professional and entrepreneurial experience in leading international business teams. As ... food testing market to uphold Eurofins, status as the global leader ... , ...
(Date:12/8/2016)... 8, 2016  Anaconda BioMed S.L., a pre-clinical stage ... next generation neuro-thrombectomy system for the treatment of Acute ... Jovin, MD to join its Scientific Advisory Board (SAB). ... network of scientific and clinical experts to Anaconda BioMed ... ANCD BRAIN ® to its clinical phase. The ...
(Date:12/8/2016)... N.J. , Dec. 8, 2016  Soligenix, ... late-stage biopharmaceutical company focused on developing and commercializing ... an unmet medical need, announced today the long-term ... with SGX942 (dusquetide), a first-in-class Innate Defense Regulator ... in head and neck cancer patients undergoing chemoradiation ...
Breaking Biology Technology:
(Date:11/19/2016)... Securus Technologies, a leading provider of civil and criminal ... monitoring, announced today that it has offered a challenge ... technology judge determine who has the largest and best ... platform, and the best customer service. "ICSolutions ... we do – which clearly is not the case ...
(Date:11/15/2016)... Md. , Nov. 15, 2016  Synthetic ... company developing therapeutics focused on the gut microbiome, ... offering of 25,000,000 shares of its common stock ... common stock at a price to the public ... proceeds to Synthetic Biologics from the offering, excluding ...
(Date:6/27/2016)... DUBLIN , June 27, 2016 Research ... in North America 2016-2020" report to their offering. ... North America to grow at a CAGR ... has been prepared based on an in-depth market analysis with inputs ... growth prospects over the coming years. The report also includes a ...
Breaking Biology News(10 mins):